Tagged with M

Egypt The table below shows highlighted markets in the MENA region, and their performance in 2013. Saudi Arabia is the largest pharma market in the region, with Iraq as the fastest growing market.

clinical trials The Mexico country manager of the Swiss biopharmaceutical company discusses the recent restructuring process the subsidiary has been going through, the strategic importance of Mexico as a logistic and clinical research hub for the region as well as how the company is going digital.     In the past ten…

regulation The executive director of the board bringing together multinational and local drug manufacturers talks about the chamber’s goal to position the pharmaceutical industry as the most important manufacturing sector in Mexico, how the chamber is working with the government and its membership to reach this goal and which new dynamics are…

Sanofi The director general of the Argentina, Uruguay and Paraguay region for Sanofi discusses the strength of the Argentinian healthcare system and the key, but subdued, role that multinational pharmaceutical companies play within it.     As someone who comes from abroad, how would you describe the environment here for multinationals?…

cardiology The general manager of Argentia weighs up the factors that have led to his company consolidating its different business lines and becoming one of the fastest growing companies in Argentina.   What was your main objective upon joining Argentia? In 1995, Argentia was acquired by BMS and was sold to…

distribution José Antonio Crespo became general manager for Beckman Coulter Iberia in July 2013, following an extensive career at Siemens. He discusses the structural changes associated with the company’s acquisition by Danaher, and outlines targets for growth in the coming years.   What initial challenges did you face at the beginning…

women's health Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets.   The crisis has changed the way companies operate in Spain, but Chemo has continued to succeed. What have been some of the key strategies employed? It has been a…

investment Newcomers to Algeria’s fledgling, but increasingly vibrant pharmaceuticals sector are immediately struck by the sense of liveliness pervading the industry. Indeed, as growth patterns in developed markets continue to flatten, and the protagonists of ‘big pharma’ pivot towards securing new revenue sources in emergent economies, Algeria must surely constitute one…

basic research Manuel Díaz-Rubio, honorary president of Spain’s Royal Academy of Medicine, traces the history of Spain’s medical community over the last few decades, and emphasizes the importance of the pharmaceutical industry to the careers of doctors and physicians across the world.   You were head of Hospital San Carlos’ gastroenterology unit…

innovation Joaquin Poch, president of the Royal Academy of Medicine of Spain, outlines the Academy’s history and current initiatives.   What are the objectives of the Royal Academy of Medicine and what are your own personal objectives as president? In order to answer this question we have to go back to…

biotech Bioceres manages investments in agricultural biotechnology and related sciences. The company’s CEO, Federico Trucco, discusses the potential of Argentina’s biotech scene to become a world-class drug developer in biopharma as well as Bioceres’ own investments in the sector.   How did you become involved with Bioceres? I have known the…

consumer healthcare GSK’s Consumer Healthcare’s regional manager for the southern cone discusses the countries longstanding commitment to the Argentinian consumer and how this history allows them to succeed in a country typically dominated by strong domestic brands.   There was recently a wave of M&A in Chile and elsewhere, do you see this…